Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company announced Thursday that its oral drug Foundayo ...
May 28, 2026 01:28 PM EDTUpdated 03:32 PM PharmaGLP-1 drugs Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook Max Bayer Senior Reporter Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that